Table 1 Clinical benefit of neratinib treatment in HER2-amplified/mutant breast cancer patients.

SD, stable disease [tumor volume (TV) changing within the +20% or −30% range compared to baseline pretreatment]; PR, partial response (TV decreasing more than 30% compared to baseline pretreatment).

PatientHER2
mutation
ERBB2 gene
copies
Best response
to neratinib
Time on
treatment (days)
AL755S9*SD141
BY772_A775dup6*SD122
CV777L11*PR166
2L313I25PR300
3R456C22SD270
4D769Y6SD180

*Response of a small cohort of patient with HER2-amplified/mutant tumors from the MSK-IMPACT database performed at the respective hospital as part of routine diagnosis and monitoring.

†Response of a small cohort of patient with HER2-amplified/mutant tumors by fluorescence in situ hybridization (FISH) performed at the respective hospital as part of routine diagnosis and monitoring.